On April 19, Mindary (300760.SZ) released its 2021 annual report, showing that in 2021 the company achieved revenue of CNY 25.270 billion, up 20.18%, achieved net profit attributable to the mother company of CNY 8.002 billion, up 20.19%. The net cash flow generated by the activity amounted to CNY 8.999 billion, and it is planned to distribute a cash dividend of CNY 35 (tax included) to all shareholders for every 10 shares.

On the same day, Mindary released its 2022 quarterly report, continuing the growth trend of 2021. In the first quarter of 2022, the company achieved operating revenue of CNY 6.943 billion, an increase of 20.10%, and net profit attributable to the mother company of CNY 2.105 billion, an increase of 22.74%.

With the development of new global medical infrastructures in the post-epidemic era, gradual recovery of routine medical treatment and medical check-up business worldwide, all three main businesses of Myriad Medical achieved double-digit growth during the reporting period, with in vitro diagnostics and medical imaging businesses growing rapidly. In the field of in vitro diagnostics, Myriad Medical achieved revenue of CNY 8.449 billion, an increase of 27.12%, and its blood cell business overtook imported brands for the first time to become the number one in China.

The high growth in in-vitro diagnostics revenue was partly due to the continued recovery of routine treatment, medical check-ups and surgeries worldwide, which led to a significant recovery in the consumption of routine reagents. On the other hand, the high growth in the in-vitro diagnostics business was driven by the rapid uptake of the new model BC-7500CRP, a fully automated blood cell analyser.

About Mindary（CACLP Booth No.A4-2001）

As a leading global provider of medical devices and solutions, Mindary's main products cover three main areas: life information and support, in vitro diagnostics, and medical imaging. Since its IPO in 2018, Mindary's revenue and net profit attributable to the parent company have maintained a steady growth of over 20%.